Study identifier:I-688
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Prevention of symptom recurrence during maintenance treatment with omeprazole 10 mg once daily or ranitidine 150 mg b.i.d for twelve months.
Acid Reflux
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|